Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 6
2002 14
2003 15
2004 17
2005 16
2006 13
2007 18
2008 7
2009 13
2010 3
2011 3
2012 5
2013 2
2014 2
2015 2
2016 5
2017 6
2018 5
2019 4
2020 3
2021 10
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

146 results
Results by year
Filters applied: . Clear all
Page 1
Selinexor for the treatment of multiple myeloma.
Podar K, Shah J, Chari A, Richardson PG, Jagannath S. Podar K, et al. Expert Opin Pharmacother. 2020 Mar;21(4):399-408. doi: 10.1080/14656566.2019.1707184. Epub 2020 Jan 19. Expert Opin Pharmacother. 2020. PMID: 31957504 Review.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Chari A, et al. Among authors: podar k. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. N Engl J Med. 2019. PMID: 31433920 Clinical Trial.
Multiple myeloma.
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Raab MS, et al. Among authors: podar k. Lancet. 2009 Jul 25;374(9686):324-39. doi: 10.1016/S0140-6736(09)60221-X. Epub 2009 Jun 21. Lancet. 2009. PMID: 19541364 Review.
Editorial: Multiple Myeloma Immunotherapies.
Podar K. Podar K. Curr Cancer Drug Targets. 2017;17(9):768. doi: 10.2174/156800961709171005160041. Curr Cancer Drug Targets. 2017. PMID: 29117857 No abstract available.
Pathway-Directed Therapy in Multiple Myeloma.
John L, Krauth MT, Podar K, Raab MS. John L, et al. Among authors: podar k. Cancers (Basel). 2021 Apr 1;13(7):1668. doi: 10.3390/cancers13071668. Cancers (Basel). 2021. PMID: 33916289 Free PMC article. Review.
Targeting the Bone Marrow Microenvironment.
Moschetta M, Kawano Y, Podar K. Moschetta M, et al. Among authors: podar k. Cancer Treat Res. 2016;169:63-102. doi: 10.1007/978-3-319-40320-5_6. Cancer Treat Res. 2016. PMID: 27696259 Review.
Cytokines and signal transduction.
Hideshima T, Podar K, Chauhan D, Anderson KC. Hideshima T, et al. Among authors: podar k. Best Pract Res Clin Haematol. 2005;18(4):509-24. doi: 10.1016/j.beha.2005.01.003. Best Pract Res Clin Haematol. 2005. PMID: 16026734 Review.
Adoptive cell therapy in multiple Myeloma.
Vallet S, Pecherstorfer M, Podar K. Vallet S, et al. Among authors: podar k. Expert Opin Biol Ther. 2017 Dec;17(12):1511-1522. doi: 10.1080/14712598.2017.1375095. Epub 2017 Sep 6. Expert Opin Biol Ther. 2017. PMID: 28857616 Review.
146 results